DIAGNOS Announces Extension of Stock Warrants Exercise Period

Core Points - Diagnos Inc. intends to extend the exercise period of 1,414,286 stock warrants from August 27, 2025, to February 27, 2029 [1][2] - The exercise price of the warrants will remain unchanged at $0.40 per common share [2] - An insider holds 357,143 of the warrants, and the amendment is exempt from certain requirements under Multilateral Instrument 61-101 due to the fair market value being below 25% of the corporation's market capitalization [3] Company Overview - Diagnos Inc. is a publicly traded Canadian corporation focused on the early detection of critical eye-related health issues using Artificial Intelligence [5] - The company's goal is to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes globally [5]